Equities

Joinn Laboratories China Co Ltd

Joinn Laboratories China Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)40.05
  • Today's Change-0.65 / -1.60%
  • Shares traded858.11k
  • 1 Year change-2.32%
  • Beta--
Data delayed at least 15 minutes, as of Feb 03 2023 08:08 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Joinn Laboratories China Co Ltd is a China-based company primarily engaged in the pharmacology and toxicology research of new drugs. Non-clinical research services include drug safety evaluation, pharmacokinetic research as well as pharmacological and pharmacodynamic research. Clinical trials and related services include clinical contract research organization services, phase I clinical research collaboration unit (CRU), and bioanalysis services. Experimental model business mainly includes rodents and non-human primates. The Company conducts its businesses both in the domestic market and overseas markets.

  • Revenue in CNY (TTM)1.94bn
  • Net income in CNY941.49m
  • Incorporated1998
  • Employees2.14k
  • Location
    Joinn Laboratories China Co LtdA5 Rongjing East StreetEconomic-Technological Development AreaBEIJING 100176ChinaCHN
  • Phone+86 1 067869582
  • Fax+86 1 067869966
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
603127:SHH since
announced
Transaction
value
Guangxi Weimei Bio-Tech Co LtdDeal completed29 Apr 202229 Apr 2022Deal completed-31.01%147.13m
Yunnan Yinmore Bio-Tech Co LtdDeal completed29 Apr 202229 Apr 2022Deal completed-31.01%125.23m
Data delayed at least 15 minutes, as of Feb 03 2023 07:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
3SBio Inc7.42bn1.99bn20.46bn5.16k11.461.468.672.760.73190.73192.725.740.3261.545.531,402,367.008.597.4210.819.0082.5281.8526.3521.794.32--0.21049.8314.2217.9497.5718.3019.71--
China Traditional Chinese Med Hldg CoLtd19.60bn1.65bn20.90bn17.36k12.660.90517.091.070.32790.32793.894.590.45741.242.491,146,444.004.185.786.638.5858.1559.579.1512.741.1113.180.239425.2028.6823.8716.2114.8634.024.93
Keymed Biosciences Inc245.12m-295.34m21.62bn474.00--5.09--88.22-5.93-5.931.5415.170.07840.674666.81754,207.60-9.68---10.61--90.61---123.50--10.12--0.0397-------374.88------
InnoCare Pharma Ltd1.38bn-345.61m27.24bn822.00--3.46--19.68-0.2442-0.24420.98314.250.16248.7825.021,919,715.00-4.10---4.26--90.01---25.22--21.01--0.1879--76,368.70--83.51------
Cansino Biologics Inc3.34bn1.15bn27.80bn2.19k14.791.9021.168.314.664.6613.5236.280.25791.155.661,718,070.008.877.0612.448.3365.65--34.3826.652.59--0.205517.0723,086.49--582.65--57.01--
Simcere Pharmaceutical Group Ltd6.50bn1.18bn31.61bn6.54k26.304.4021.504.860.45170.45172.492.700.56113.752.721,052,095.0010.12--15.22--78.84--18.03--1.67--0.1975--10.89--125.10------
Zai Lab Ltd1.54bn-4.65bn31.97bn1.95k--3.61--20.73-4.87-4.871.619.040.12993.598.07---39.16---42.96--61.96---301.41-656.137.59--0.00--194.77---161.98--53.42--
AIM Vaccine Co Ltd-100.00bn-100.00bn32.70bn---------------------------------------------------4.14---282.65------
Joinn Laboratories China Co Ltd2.05bn903.26m36.61bn2.28k23.712.4835.3317.861.691.693.8316.140.191.239.01958,191.608.36--10.69--48.04--43.99--1.74--0.0119--40.97--78.13------
Akeso Inc303.28m-1.49bn41.13bn2.29k--13.14--135.61-1.83-1.830.37193.720.05320.28731.02162,615.70-30.75---36.86--76.91---578.04--2.40-148.900.3322-------3.72------
RemeGen Co Ltd1.66bn322.04m51.83bn2.12k103.708.50112.0731.220.67260.67263.418.200.34410.3877403.94782,597.606.68--7.64--95.28--19.40--3.2853.140.029------139.59------
Data as of Feb 03 2023. Currency figures normalised to Joinn Laboratories China Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

30.55%Per cent of shares held by top holders
HolderShares% Held
UBS Asset Management (Hong Kong) Ltd.as of 17 Jan 20235.43m6.39%
Abrdn Asia Ltd.as of 31 Dec 20224.63m5.45%
APG Asset Management NVas of 31 Aug 20224.18m4.92%
JPMorgan Asset Management (Asia Pacific) Ltd.as of 25 Feb 20222.38m2.81%
UBS Asset Management (Japan) Ltd.as of 17 Jan 20232.22m2.61%
China Universal Asset Management Co., Ltd.as of 30 Jun 20221.69m1.99%
ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 20221.55m1.82%
The Vanguard Group, Inc.as of 05 Jan 20231.44m1.69%
Zhong Ou Asset Management Co., Ltdas of 31 Dec 20211.40m1.65%
UBS Asset Management Switzerland AGas of 17 Jan 20231.04m1.22%
More ▼
Data from 30 Jun 2022 - 30 Nov 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.